CIK 0000882095 · Large accelerated filer
GILEAD SCIENCES, INC.
Sign in to watch- Ticker
- GILD
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 943047598
- Phone
- 6505743000
- Business address
- 333 LAKESIDE DR, FOSTER CITY, CA, 94404
- Former names
- GILEAD SCIENCES INC
- SCHEDULE 13D Stake Beneficial Ownership Report
- SC TO-C Deal Written Communication Relating to an Issuer
- 8-K Event Material agreement · Regulation FD disclosure
- 4 Planned sale Chief Comm & Corp Aff Officer sold 28,000 shares at an average $154.44 ($4,324,228)
- 4 Planned sale Chief Financial Officer sold 3,000 shares at $154.43 ($463,290)
- 4 Derivatives Options or other derivatives
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 3 Insider Initial Statement of Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 13F-HR Other Quarterly Holdings of Institutional Investment Managers
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 8-K Event Results of operations
- 4 Planned sale Chairman & CEO sold 115,640 shares at $150.00 ($17,346,000)
- 4 Shares withheld for taxes Chief Comm & Corp Aff Officer gave up 24,800 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Financial Officer gave up 24,802 shares (to pay taxes)
- 4 Shares withheld for taxes Chairman & CEO gave up 74,461 shares (to pay taxes)
- 144 Insider Sale of Securities
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 4 Planned sale Chairman & CEO sold 10,000 shares at an average $139.89 ($1,398,911)
Page 7 of 160 · 3,186 filings